Matteo Lambertini, MD, on Preserving Fertility in Patients With Early Breast Cancer: Pooled Analysis
2017 San Antonio Breast Cancer SymposiumMatteo Lambertini, MD, of the Institut Jules Bordet, discusses the results of five clinical trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (Abstract GS4-01).
Related Videos
Eun-Sil Shelley Hwang, MD, on DCIS: Results of the CALGB 40903 Trial
Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstrac...
Nicholas C. Turner, MD, PhD, on Tackling Breast Cancer Diversity
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to ...
Harold J. Burstein, MD, PhD, on HR+ Early Breast Cancer: Update of the SOFT Trial
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses study findings on a comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in p...
Richard G. Gray, MSc, on Adjusting Adjuvant Chemotherapy Dosing: Results From an EBCTCG Analysis
Richard G. Gray, MSc, of the University of Oxford, discusses an Early Breast Cancer Trialists’ Collaborative Group meta-analysis of 21,000 women in 16 randomized trials, which show...
Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial
Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a no...
